ClinicalTrials.gg
RecruitingNCT05243771Updated May 24, 2023

Norwegian Stoma Trial

An observational study in Rectal Cancer, Ileostomy; Complications and Quality of Life, sponsored by The Hospital of Vestfold. Recruiting at 18 sites in Norway. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by The Hospital of Vestfold · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Rectal Neoplasms with a site in Norway — 6 open to participants now, 12 under way, 3 of them phase 3. Rectal Neoplasms · Norway.

Planned enrollment
3rd of 11
400 · median 192
Started
2022
with 4 others
Observational
11 of 25
4 open now
Primary completion
2025-08
later than 5 of 11 live
Registered
19th of 25
by date

Among the 25 studies in Rectal Neoplasms with a site in Norway, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2022, is one of 11 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 19th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

6 of the 25 studies in Rectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Rectal Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

The Norwegian Stoma Trial is an open-label multicenter trial investigating the use of stomas, both diveriting and permanent, in the surgical treatment of rectal cancer. The objective is to compare the chosen strategy to surgical complications, health realted quality of life and length of stay.

Read the detailed description

In this national, multicenter study the study group will investigate whether patients with rectal adenocarcinoma undergoing a resection with an anastomosis will benefit from a diverting stoma or not, by studying how choice of surgery affects complications. In addition the study group will investigate complication rates and HRQoL among patients receiving a permanent colostomy and compare this to patients who have received an anastomosis. The investigators know that there are different approaches to the use of stomas (both permanent and diverting) between different hospitals. The investigators aim to discover potential differences in complication rates, length of stay and HRQoL among these patients and compare this to the chosen strategy. Health related quality of life will be measured using the EORTC CR 29 and EORTC CR 30 questionnares. Bowel function will also be monitored using the LARS (low anterior resection syndrome) score.

03

Conditions studied

  • Rectal Cancer
  • Ileostomy; Complications
  • Quality of Life
  • Complication,Postoperative
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patients undergoing a formal resection for rectal cancer will be asked to participate as long as they fit the eligibility criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Verified rectal adenocarcinoma by
  • Tumor located in the rectum with lower border of the tumor located 15 cm or less from the anal verge.
  • Given

Exclusion criteria

Exclusion Criteria:

  • Advanced tumor stage requiring exenterative surgery beyond a convetional APR or TME.
  • Stage IV disease
  • Synchronous colon cancer necessitating a total colectomy
  • Other concomitant disease(s) which will complicate participation.
  • Unwillingness to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rectal resection with diverting stoma

    Patients operated for rectal cancer with rectal resection and diverting stoma.

    Procedure: Rectal resection with diverting stoma

  • Rectal resection without diverting stoma

    Patients operated for rectal cancer with rectal resection without diverting stoma.

    Procedure: Rectal resection without diverting stoma

  • Rectal resection with primary colostomy

    Patients operated for rectal cancer with rectal resection with primary colostomy.

    Procedure: Rectal resection with permanent colostomy

Interventions

  • ProcedureRectal resection with diverting stoma

    Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created

  • ProcedureRectal resection without diverting stoma

    Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created

  • ProcedureRectal resection with permanent colostomy

    Patients in this group will receive a rectal resection and a permanent colostomy will be created

06

What researchers measure

Primary outcomes

  1. Surgical complications graded as Accordion grade 3 or more

    The study group will investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have higher complication rates compared to patients who do not recieve a diverting stoma.

    Time frame: Measured one year after the primary surgery

Secondary outcomes

  1. Total length of hospital stay

    Number of days admitted at hospital. The study group will investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have a higher number of days admitted to hospital compared to patients who do not recieve a diverting stoma.

    Time frame: Measured one year after the primary surgery

  2. Generic health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) C30 questionnaire

    Generic health related quality of life is measured using the EORTC C30 questionnaire. Investigate whether patients receiving a rectal resection with a primary colostomy have poorer health related quality of life compared to patients receiving an anastomosis.

    Time frame: One year after the primary surgery

  3. Bowel function measured by the Low Anterior Resection Syndrome (LARS) score

    Bowel function is measured using the Low Anterior Resection Syndrome score. The score ranges from 0 to 42 points The higher the score, the worse the bowel function. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have higher LARS scores compared to patients who do not recieve a diverting stoma.

    Time frame: One year after the primary surgery

  4. Surgical complications graded as Accordion grade 3 or more

    Investigate whether patients receiving a rectal resection with a primary colostomy have lower complication rates compared to patients receiving an anastomosis

    Time frame: Measured one year after the primary surgery

  5. Generic health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) C30 questionnaire.

    Generic health related quality of life is measured using the EORTC C30 questionnaire. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have poorer health related quality of life compared to patients who do not recieve a diverting stoma.

    Time frame: One year after the primary surgery

  6. Disease specific health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) CR29 questionnnaire

    Disease specific health related quality of life measured by the EORTC CR29 questionnnaire. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have poorer health related quality of life compared to patients who do not recieve a diverting stoma.

    Time frame: One year after the primary surgery

  7. Disease specific health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) CR29 questionnnaire.

    Disease specific health related quality of life measured by the EORTC CR29 questionnnaire. Investigate whether patients receiving a rectal resection with a primary colostomy have poorer health related quality of life compared to patients receiving an anastomosis.

    Time frame: One year after the primary surgery

07

Study locations

18 of 18 sites recruiting
  • Asker og Baerum Hospital
    Bærums Verk, Gjettum 1346, Norway
    Recruiting
    • Mathias Irgens, MD · Contact
  • Østfold Hospital Trust
    Sarpsborg, Grålum 1714, Norway
    Recruiting
    • Silje Sanengen, MD · Contact
  • Akershus University Hospital
    Oslo, Lørenskog 1478, Norway
    Recruiting
    • Thomas Heggelund, MD · Contact
  • Haukeland University Hospital
    Bergen, 5009, Norway
    Recruiting
    • Håvard Forsmo, MD, PhD · Contact
  • Bodø Hospital
    Bodø, 8005, Norway
    Recruiting
    • Kåre Nordland, MD · Contact
  • Vestre Viken Hospital Trust
    Drammen, 3004, Norway
    Recruiting
    • Johan Bondi, MD, PhD · Contact
  • Gjøvik Hospital
    Gjøvik, 2819, Norway
    Recruiting
    • Alexander Frodahl, MD · Contact
  • Hamar Hospital
    Hamar, 2318, Norway
    Recruiting
    • Jan Lambrecht, MD, PhD · Contact
  • Helse Fonna
    Haugesund, 5528, Norway
    Recruiting
    • Håvard Thorsen, MD · Contact
  • Sorlandet Hospital HF
    Kristiansand, 4615, Norway
    Recruiting
    • Martin Bøhler, MD · Contact
  • Helse Nord-Trøndelag HF
    Levanger, 7600, Norway
    Recruiting
    • Eivor Laugsand, MD, PhD · Contact
  • Ullevaal University Hospital
    Oslo, 0450, Norway
    Recruiting
    • Usman Saeed, MD · Contact
  • Sykehuset Telemark
    Skien, 3710, Norway
    Recruiting
    • Silje Holte, MD · Contact
  • Helse Stavanger HF
    Stavanger, 4019, Norway
    Recruiting
    • Ragnar Herikstad, MD · Contact
  • University Hospital of North Norway
    Tromsø, 9019, Norway
    Recruiting
    • Martin Hagve, MD · Contact
  • St. Olavs Hospital
    Trondheim, 7030, Norway
    Recruiting
    • Tore Stornes, MD, PhD · Contact
  • Vestfold Hospital Trust
    Tønsberg, 3103, Norway
    Recruiting
    • Lars Grønvold, MD · Contact
  • Ålesund Hospital
    Ålesund, 6017, Norway
    Recruiting
    • Thomas Nygaard, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Aug 2025, 35 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 35 months is below that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Feb 17, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243771
Lead sponsor
The Hospital of Vestfold
Collaborators
Haukeland University Hospital, University Hospital of North Norway, Helse Nord-Trøndelag HF, St. Olavs Hospital, Alesund Hospital, Helse Fonna, Helse Stavanger HF, Sorlandet Hospital HF, Sykehuset Telemark, Vestre Viken Hospital Trust, Asker & Baerum Hospital, Ullevaal University Hospital, Oslo University Hospital, Ostfold Hospital Trust, University Hospital, Akershus, Hamar Hospital, Gjøvik Hospital, Bodø Hospital
Responsible party
Lars Thomas (Principal Investigator, The Hospital of Vestfold) — Principal investigator
First posted
Feb 17, 2022
Start date
Sep 1, 2022
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
May 24, 2023

Study contacts

Lars Thomas Seeberg, MD, PhD
Contact
ltseeberg@gmail.com
+4733342000
Lars Grønvold, MD
Contact
lagr1@siv.no
+4733342000
Lars Thomas Seeberg, MD, PhD
principal investigator · The Hospital of Vestfold

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion